EETs Reduction Contributes to Granulosa Cell Senescence and Endometriosis‐Associated Infertility via the PI3K/AKT/mTOR Signaling Pathway
Source abstract
Abstract
Abstract We aimed to examine abnormal oxidative lipid levels and their related mechanisms in EM‐associated infertility. Through liquid chromatography tandem mass spectrometry analysis, decreased levels of epoxyeicosatrienoic acids (EETs), which have antioxidant and anti‐senescence effects are observed, in EM patient follicular fluid samples. EET levels are positively correlated with in vitro fertilization outcomes. Lower 14, 15‐EET concentrations led to a decreased GC antioxidant capacity, reduced ATP production, reactive oxygen species (ROS) accumulation in oocytes, and abnormal cumulus‐oocyte complex (COC) expansion, ultimately resulting in decreased fertility. Elevated soluble epoxide hydrolase (EPHX2) expression in EM‐GCs is the main reason for EET reduction in EM follicular fluid. Inhibiting EPHX2 in vivo or in vitro can reverse these observed abnormalities by upregulating EETs. 14, 15‐EET treatment alleviated GC senescence and improved fertility by inhibiting excessive PI3K/AKT/mTOR signaling pathway activation in EM‐GCs, with BEZ‐235‐mediated inhibition of this pathway significantly alleviating ROS‐induced cell senescence and abnormal COC expansion. Oxidative stress‐induced decreased EZH2/H3K27Me3 histone methylation led to elevated EPHX2 expression patterns in EM‐GCs. Decreased 14, 15‐EET levels resulted in ROS accumulation, reduced EZH2 enzymatic activity, less EPHX2/H3K27Me3 histone methylation, and increased EPHX2 protein expression levels, which further reduced 14, 15‐EET levels in a vicious feedback loop.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Endometriosis Research and Treatment · Apelin-related biomedical research · Ovarian function and disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Assisted Reproduction Unit Department of Obstetrics and Gynecology Sir Run Run Shaw Hospital Zhejiang University School of Medicine No. 3 Qingchun East Road, Shangcheng District Hangzhou 310016 China
Key Laboratory of Reproductive Dysfunction Management of Zhejiang Province No. 3 Qingchun East Road, Shangcheng District Hangzhou 310016 China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province · National Key Research and Development Program of China
References (61)
Show source-provided references
1. 10.1111/aogs.1308210.1111/aogs.13082 ↗
2. 10.1016/j.redox.2020.10143110.1016/j.redox.2020.101431 ↗
3. 10.1016/j.bpobgyn.2023.10245410.1016/j.bpobgyn.2023.102454 ↗
4. 10.1016/S0140-6736(10)60490-410.1016/S0140-6736(10)60490-4 ↗
5. 10.1016/j.redox.2020.10172610.1016/j.redox.2020.101726 ↗
6. 10.1038/s41598-018-37766-210.1038/s41598-018-37766-2 ↗
7. 10.1007/s00441-015-2339-910.1007/s00441-015-2339-9 ↗
8. 10.1002/path.607910.1002/path.6079 ↗
9. 10.1210/endocr/bqac21010.1210/endocr/bqac210 ↗
10. 10.1016/j.cell.2023.08.00310.1016/j.cell.2023.08.003 ↗
11. 10.1016/j.cell.2022.11.00110.1016/j.cell.2022.11.001 ↗
12. 10.1007/s00204-023-03476-610.1007/s00204-023-03476-6 ↗
13. 10.1111/cas.1413210.1111/cas.14132 ↗
14. 10.1038/s41589-022-01249-310.1038/s41589-022-01249-3 ↗
15. Zhao H. · Int. J. Mol. Sci. · 2021 · 14 · 22
16. 10.3390/ijms2209465010.3390/ijms22094650 ↗
17. 10.1016/j.redox.2020.10143110.1016/j.redox.2020.101431 ↗
18. 10.2147/JIR.S27559510.2147/JIR.S275595 ↗
19. Zhang C. Y. · Redox Biol. · 2023 · 63
20. 10.3390/ijms2309495110.3390/ijms23094951 ↗
21. Ren Q. · P Natl Acad Sci USA · 2016 · 113
22. 10.1016/j.prostaglandins.2015.06.00510.1016/j.prostaglandins.2015.06.005 ↗
23. 10.1111/j.1476-5381.2011.01641.x10.1111/j.1476-5381.2011.01641.x ↗
24. Wu Y. · Neuron · 2023 · 111 · 2810
25. 10.1161/STROKEAHA.124.04914310.1161/STROKEAHA.124.049143 ↗
26. 10.1080/14756366.2024.244771910.1080/14756366.2024.2447719 ↗
27. 10.1016/j.gene.2012.09.01610.1016/j.gene.2012.09.016 ↗
28. 10.1021/acs.jmedchem.2c0199610.1021/acs.jmedchem.2c01996 ↗
29. 10.1016/j.ijbiomac.2021.04.18710.1016/j.ijbiomac.2021.04.187 ↗
30. 10.1016/j.drudis.2021.05.01710.1016/j.drudis.2021.05.017 ↗
31. 10.3390/ijms2309495110.3390/ijms23094951 ↗
32. 10.1016/j.coph.2024.10247710.1016/j.coph.2024.102477 ↗
33. 10.3390/ijms2201001310.3390/ijms22010013 ↗
34. 10.1016/j.jsbmb.2023.10643910.1016/j.jsbmb.2023.106439 ↗
35. 10.1007/s10522-018-9785-110.1007/s10522-018-9785-1 ↗
36. 10.1155/2024/310094210.1155/2024/3100942 ↗
37. 10.1016/j.bbrc.2013.02.10810.1016/j.bbrc.2013.02.108 ↗
38. Liu G. · Aging Dis. · 2023 · 14 · 1425
39. 10.1186/s13287-023-03297-510.1186/s13287-023-03297-5 ↗
40. 10.3390/ijms2313696010.3390/ijms23136960 ↗
41. 10.1016/j.phymed.2021.15366410.1016/j.phymed.2021.153664 ↗
42. 10.1016/j.bbamcr.2022.11941110.1016/j.bbamcr.2022.119411 ↗
43. 10.3389/fendo.2021.70244610.3389/fendo.2021.702446 ↗
44. 10.1210/er.2014-102010.1210/er.2014-1020 ↗
45. 10.1016/j.semcancer.2019.07.00910.1016/j.semcancer.2019.07.009 ↗
46. 10.1002/med.2180210.1002/med.21802 ↗
47. 10.1016/j.biopha.2023.11490910.1016/j.biopha.2023.114909 ↗
48. 10.1111/bph.1439110.1111/bph.14391 ↗
49. 10.1139/cjpp-2019-015610.1139/cjpp-2019-0156 ↗
50. 10.1210/en.2017-0322710.1210/en.2017-03227 ↗
51. Dai Y. D. · Cell Death Dis. · 2019 · 10
52. 10.3892/mmr.2021.1227610.3892/mmr.2021.12276 ↗
53. Showell M. G. · Cochrane Database Syst Rev. · 2020 · 8
54. 10.1002/jcp.3046810.1002/jcp.30468 ↗
55. 10.1186/1477-7827-10-4910.1186/1477-7827-10-49 ↗
56. 10.1186/1471-2407-14-54810.1186/1471-2407-14-548 ↗
57. 10.1073/pnas.120281010910.1073/pnas.1202810109 ↗
58. 10.1016/0002-9378(93)90642-V10.1016/0002-9378(93)90642-V ↗
59. 10.1038/s41419-019-1395-610.1038/s41419-019-1395-6 ↗
60. Pelch K. E. · J. Visualized Exp. · 2012 · 59
61. 10.1210/me.2010-014110.1210/me.2010-0141 ↗